Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL28591585 | 1.00 | GSR (0.47) | GSRCPB2RNPEPGABRR1LTA4H | |
| SCHEMBL7593236 | 0.93 | CPB2 (0.49) | GSRCPB2RNPEPGABRR1FOLH1 | |
| SCHEMBL7593232 | 0.93 | CPB2 (0.49) | GSRCPB2RNPEPGABRR1FOLH1 | |
| SCHEMBL8200953 | 0.91 | CPB2 (0.51) | GSRCPB2RNPEPGABRR1FOLH1 | |
| SCHEMBL4727761 | 0.88 | GABRR1 (0.43) | GSRCPB2RNPEPGABRR1FOLH1 | |
| SCHEMBL4727762 | 0.88 | GABRR1 (0.43) | GSRCPB2RNPEPGABRR1FOLH1 | |
| SCHEMBL19742925 | 0.88 | GABRR1 (0.43) | GSRCPB2RNPEPGABRR1FOLH1 | |
| SCHEMBL4299117 | 0.86 | GSR (0.38) | GSRCPB2RNPEPGABRR1LTA4H | |
| SCHEMBL29689829 | 0.84 | GSR (0.42) | GSRCPB2RNPEPGABRR1LTA4H | |
| D-Alanine SCHEMBL5702871 | 0.84 | GSR (0.39) | GSRCPB2RNPEPGABRR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158101-A1 | GLYCOPEPTIDE COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. | 2023-05-25 | — | — | US | disclosed |
| US-11628200-B2 | Glycopeptide compositions | XELLIA PHARMACEUTICALS APS (DK) | 2023-04-18 | — | — | US | disclosed |
| EP-4147710-A1 | GLYCOPEPTIDE COMPOSITIONS IN SOLUTION | Xellia Pharmaceuticals ApS (DK) | 2023-03-15 | — | — | EP | disclosed |
| US-11517609-B2 | Glycopeptide compositions | XELLIA PHARMACEUTICALS APS (DK) | 2022-12-06 | — | — | US | disclosed |
| US-11168077-B2 | Molecular rotor-based D-amino acids as tools for imaging peptidoglycan biosynthesis | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210220433-A1 | Glycopeptide Compositions | XELLIA PHARMACEUTICALS APS (DK) | 2021-07-22 | — | — | US | disclosed |
| EP-3834837-A1 | GLYCOPEPTIDE COMPOSITIONS | Xellia Pharmaceuticals ApS (DK) | 2021-06-16 | — | — | EP | disclosed |
| US-11000567-B2 | Glycopeptide compositions | XELLIA PHARMACEUTICALS APS | 2021-05-11 | — | — | US | disclosed |
| US-20210047308-A1 | MOLECULAR ROTOR-BASED D-AMINO ACIDS AS TOOLS FOR IMAGING PEPTIDOGLYCAN BIOSYNTHESIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-02-18 | — | — | US | disclosed |
| EP-3542812-B1 | GLYCOPEPTIDE COMPOSITIONS | XELLIA PHARMACEUTICALS APS (DK) | 2021-01-13 | — | — | EP | disclosed |
| US-20170348385-A1 | GLYCOPEPTIDE COMPOSITIONS | HIKMA PHARMACEUTICALS USA INC. | 2017-12-07 | — | — | US | disclosed |
| EP-3215173-A1 | GLYCOPEPTIDE COMPOSITIONS | Xellia Pharmaceuticals ApS (DK) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016071495-A1 | GLYCOPEPTIDE COMPOSITIONS | XELLIA PHARMACEUTICALS APS (DK) | 2016-05-12 | — | — | WO | disclosed |
| US-7556932-B2 | Particle based homogeneous assays using capillary electrophoresis with laser-induced fluorescence detection | BECKMAN COULTER, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20070259338-A1 | Detection of preferential particles in sample; provide sensitized particles, incubate with sample, expose to capillary electrophoresis, determine concentration of particles in sample | BECKMAN COULTER, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-7179658-B2 | Particle based homogeneous assays using capillary electrophoresis with laser-induced fluorescence detection | BECKMAN COULTER, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1432987-A4 | PARTICLE BASED HOMOGENEOUS ASSAYS USING CAPILLARY ELECTROPHORESIS WITH LASER-INDUCED FLUORESCENCE DETECTION | BECKMAN COULTER INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1432987-A2 | PARTICLE BASED HOMOGENEOUS ASSAYS USING CAPILLARY ELECTROPHORESIS WITH LASER-INDUCED FLUORESCENCE DETECTION | Beckman Coulter, Inc. (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003023353-A2 | PARTICLE BASED HOMOGENEOUS ASSAYS USING CAPILLARY ELECTROPHORESIS WITH LASER-INDUCED FLUORESCENCE DETECTION | BECKMAN COULTER, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| US-20030054569-A1 | Particle based homogeneous assays using capillary electrophoresis with laser-induced fluorescence detection | BECKMAN COULTER, INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517609-B2 | Glycopeptide compositions | ASNS, B3GNT2, OGT | GSR 2714/4885CPB2 1171/4885RNPEP 63/4885 |
| US-11000567-B2 | Glycopeptide compositions | ASNS, B3GNT2, OGT | GSR 2714/4885CPB2 1171/4885RNPEP 63/4885 |
| US-20230158101-A1 | GLYCOPEPTIDE COMPOSITIONS | ASNS, OGT, B3GNT2 | GSR 3752/4885CPB2 1397/4885RNPEP 69/4885 |
| US-20210220433-A1 | Glycopeptide Compositions | ASNS, B3GNT2, OGT | GSR 2714/4885CPB2 1171/4885RNPEP 63/4885 |
| US-11628200-B2 | Glycopeptide compositions | ASNS, B3GNT2, OGT | GSR 2714/4885CPB2 1171/4885RNPEP 63/4885 |
| US-20170348385-A1 | GLYCOPEPTIDE COMPOSITIONS | ASNS, B3GNT2, OGT | GSR 2714/4885CPB2 1171/4885RNPEP 63/4885 |
| US-11168077-B2 | Molecular rotor-based D-amino acids as tools for imaging peptidoglycan biosynthesis | DDOST, DAD1, DAO | GSR 2480/4885CPB2 1303/4885RNPEP 266/4885 |
| US-20210047308-A1 | MOLECULAR ROTOR-BASED D-AMINO ACIDS AS TOOLS FOR IMAGING PEPTIDOGLYCAN BIOSYNTHESIS | DDOST, DAD1, DAO | GSR 2480/4885CPB2 1303/4885RNPEP 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.